PERKINS CAPITAL MANAGEMENT INC - HTG MOLECULAR DIAGNOSTICS IN ownership

Quarter-by-quarter ownership
PERKINS CAPITAL MANAGEMENT INC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$802,000
+1.4%
2,426,300
-0.3%
0.74%
-22.9%
Q1 2020$791,000
-55.4%
2,434,000
-3.7%
0.96%
-39.9%
Q4 2019$1,774,000
+13.4%
2,527,000
+7.4%
1.59%
+18.0%
Q3 2019$1,564,000
+58.9%
2,353,153
+297.1%
1.35%
+95.6%
Q2 2019$984,000
-36.5%
592,620
-4.4%
0.69%
-32.5%
Q1 2019$1,550,000
+35.6%
619,920
+37.8%
1.02%
+15.2%
Q4 2018$1,143,000
-9.4%
449,950
+80.2%
0.89%
+17.0%
Q3 2018$1,261,000
+54.9%
249,7000.0%0.76%
+29.8%
Q2 2018$814,000
-10.1%
249,700
-0.2%
0.58%
-28.5%
Q1 2018$905,000250,1000.82%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
PERKINS CAPITAL MANAGEMENT INC 2,426,300$802,0000.74%
Cowen Prime Services LLC 1,411,500$466,0000.23%
GSA CAPITAL PARTNERS LLP 1,205,873$398,0000.07%
Nantahala Capital Management 5,113,958$1,690,0000.05%
HighMark Wealth Management LLC 80,000$26,0000.02%
Kalos Management, Inc. 72,858$24,0000.01%
Qube Research & Technologies Ltd 585,187$193,0000.00%
WINTON GROUP Ltd 190,146$63,0000.00%
Ironwood Financial, llc 1,571$1,0000.00%
Virtu Financial LLC 12,049$4,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders